Danaher Corporation  

(Public, NYSE:DHR)   Watch this stock  
Find more results for DHR
-0.07 (-0.09%)
Jan 20 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 80.12 - 80.91
52 week 75.71 - 102.79
Open 80.84
Vol / Avg. 2.21M/3.12M
Mkt cap 55.65B
P/E 26.30
Div/yield 0.12/0.62
EPS 3.06
Shares 691.70M
Beta 1.04
Inst. own 78%
Jan 24, 2017
Q4 2016 Danaher Corp Earnings Release (Estimated) - 6:00AM EST - Add to calendar
Dec 15, 2016
Danaher Corp 2016 Investor & Analyst Meeting
Nov 9, 2016
Danaher Corp at Robert W Baird Global Industrial Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 9.74% 12.64%
Operating margin 12.59% 16.87%
EBITD margin - 22.58%
Return on average assets 3.48% 6.10%
Return on average equity 6.70% 11.04%
Employees 81,000 -
CDP Score - 22


2200 Pennsylvania Ave NW Ste 800w
WASHINGTON, DC 20037-1731
United States - Map
+1-202-8280850 (Phone)
+1-202-8280860 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates in five segments: Test & Measurement; Environmental; Life Sciences & Diagnostics; Dental, and Industrial Technologies. The Test & Measurement segment offers products, software and services. Its Environmental segment products and services help protect the water supply, enhance the safety of personal data and improve business efficiencies. In the Life Sciences & Diagnostics segment, its diagnostics business offers analytical instruments, reagents, consumables, software and services. Its life sciences business offers research tools. Its Dental segment provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. Its Industrial Technologies segment solutions help protect the world's food supply, improve packaging design and quality, and verify pharmaceutical dosages.

Officers and directors

Steven M. Rales Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel L. Comas Chief Financial Officer, Executive Vice President
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
William K. Daniel II Executive Vice President
Age: 51
Bio & Compensation  - Reuters
Robert S. Lutz Senior Vice President, Chief Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Brian W. Ellis Senior Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Angela S. Lalor Senior Vice President - Human Resources
Age: 50
Bio & Compensation  - Reuters
William H. King Senior Vice President- Strategic Development
Age: 48
Bio & Compensation  - Reuters
Daniel A. Raskas Senior Vice President - Corporate Development
Age: 49
Bio & Compensation  - Reuters
Thomas Patrick Joyce Jr. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Donald J. Ehrlich Lead Independent Director
Age: 78
Bio & Compensation  - Reuters